General Introduction

The Department of Hepatobiliary Surgery at Tianjin Medical University Cancer Institute and Hospital (TMUCIH) has a long history of being at the forefront of education, research, and clinical care. The department of hepatobiliary surgery deals with the diagnosis, treatment and management of benign and malignant diseases of the liver, pancreas, biliary tract, spleen and allied diseases. The department currently staffs 118 general beds. Nearly 20,000 out-patients visit the department each year, among which 4,000 are admitted in the in-patient department, and over 2,000 operations have been performed per year. The mission of the department is to provide excellent patient care in an environment that stimulates its faculty, trainees and students to constantly improve their patient care, teaching, learning and investigation abilities.

Faculty / Staff

The department includes 17 surgeons and 1 scientific researcher. All the surgeons are training representing the entire spectrum of surgical experience, including the director Tianqiang Song, three chief physician, four associate chief physicians and nine doctors with PhD degree.



The departments also attach importance to the research of transformational medicine and strengthen the cooperation with relevant basic research departments. At present, there are 4 projects of the National Natural Science Foundation of China (NSFC), 3 major sub-projects of the The National Science and Technology Major Project of China, and 2 projects of The Science & Technology Development Fund of Tianjin Education Commission for Higher Education. Between 2016 and 2018, 17 SCI papers and 7 Chinese series magazines were published, 9 other core journals were published. In 2017, the project of "Basic and Clinical Integration Research on Heterogeneity of Malignant Tumors such as Hepatocellular Carcinoma" was selected as the "13th Five-Year Plan" for the Promotion of Advantage Disciplines in the Construction of Comprehensive Investment Disciplines.


Clinical Service

The Department of Hepatobiliary Surgery focuses on primary, secondary hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer. The development of technology has always been our goal. Accurate hepatobiliary tumor resection, laparoscopic hepatobiliary tumor resection, robotic hepatobiliary tumor resection, including percutaneous, laparoscopic and laparotomy radiofrequency ablation have been routinely carried out. The establishment of MDT team for hepatobiliary tumors in 2011 has been running successfully so far. It is one of the three best teams for MDT development and the earliest department for rapid rehabilitation surgery in the hospital (2007). At present, ERAS concept has been widely developed in the department of Hepatobiliary Surgery and has become a conventional technology. The undergraduate has abundant clinical case resources, and has established a complete tissue specimen bank, serum specimen bank and clinical pathological data database. At present, it undertakes 12 international and domestic multi-center clinical trials. It is one of the earliest surgical departments in the hospital to carry out clinical trials. All doctors have GCP certification. In 2017, Postoperative adjuvant chemotherapy for biliary tract tumors was selected as one of the three key projects in the hospital's clinical research.

For the future, the Department of Hepatobiliary Surgery will continue to practice the philosophy, as it has been, of "treating patients as family and pursuing excellence," and incorporate the philosophy into medical service, medical teaching and medical research, the three main tasks of the Department. With a humanist mind, the ultimate goal of the Department is to seek the health and wellbeing of the mankind.

Our Team
Wei Lu M.D., Ph.D.
Party Secretary of TMUCIH
Qiang Li M.D.
Tianqiang Song M.D.